Companies /Healthcare

Ocugen Inc

NASDAQ: OCGN Biotechnology
$1.05
▲ $0.03 (+2.44%) today
Markets open · 11:49am ET

Q3 2025 Earnings

Reported Nov 5, 2025, 7:30am ET · SEC source
$-0.07
Miss −21.74%
EPS · est. $-0.06
$1.8M
Beat +298.18%
Revenue · est. $440,000
−15.8%
Trailing market
OCGN vs S&P since report
4 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−5%0+5%Nov 5Nov 6report 7:30am ETearnings−0.4%−5.4%
−5%0+5%Nov 5Nov 6earnings−0.4%−5.4%
OCGN −5.4%S&P 500 −0.4%
−5%0+5%Nov 5Nov 6report 7:30am ETearnings−0.6%−5.4%
−5%0+5%Nov 5Nov 6earnings−0.6%−5.4%
OCGN −5.4%NASDAQ −0.6%
−15%−10%−5%0Nov 4Nov 13report 7:30am ETearnings+0.9%−10.7%
−15%−10%−5%0Nov 4Nov 13earnings+0.9%−10.7%
OCGN −10.7%S&P 500 +0.9%
−15%−10%−5%0Nov 4Nov 13report 7:30am ETearnings−0.0%−10.7%
−15%−10%−5%0Nov 4Nov 13earnings−0.0%−10.7%
OCGN −10.7%NASDAQ −0.0%
−1.40%
Day of report
−2.13%
Next session
−4.96%
One week
−14.89%
30 days

S&P 500 over the same 30 days: +0.89%.

Did OCGN Beat Earnings? Q3 2025 Results

Ocugen delivered a mixed third quarter for fiscal 2025, posting a loss that widened beyond expectations even as revenue dramatically exceeded forecasts, painting a picture of a clinical-stage biotech burning cash to fuel an ambitious pipeline. The company earned $1.75 million in revenue, a 54.2% jump year-over-year that blew past the $440,000 consensus estimate by 298.18%, largely driven by the licensing deal with Kwangdong Pharmaceutical for OCU400 rights in South Korea. On the bottom line, however, Ocugen missed, reporting a loss of $0.07 per share against the $0.06 consensus estimate, a 21.74% shortfall, as operating expenses climbed to $19.38 million from $14.39 million a year ago on heavier R&D and clinical trial spending. The net loss widened to $20.05 million, leaving cash at $32.90 million with a runway extending only through Q2 2026, though warrant proceeds could push that into 2027. Looking ahead, the company is targeting a BLA rolling submission for OCU400 in H1 2026, with top-line Phase 3 data expected by Q4 2026, as management advances its goal of filing three BLAs over the next three years.

Key Takeaways
  • Revenue growth from collaborative arrangement revenue related to Kwangdong licensing deal
  • Increased R&D spending driven by advancing multiple late-stage clinical trials
  • Higher G&A expenses supporting expanded operations

“With two late-stage modifier gene therapies on track to meet 2026 and 2027 BLA/MAA filings, it's remarkable to look back and recognize we only began dosing the first patient in the Phase 1/2 OCU400 clinical trial in 2022. The OCU410ST Phase 2/3 GARDian3 pivotal confirmatory trial is following close behind the OCU400 Phase 3 liMeLiGhT clinical trial, and with 50% enrollment completed to date, we believe recruitment will be completed in the first quarter of 2026. This progress not only reinforces our commitment to file three BLAs in the next three years, but it also brings us closer to addressing the incredible unmet medical needs that exist for patients facing vision loss.”

Ocugen CEO, on the earnings call

Forward Guidance & Outlook

Ocugen expects current cash of $32.9 million to provide runway through Q2 2026, with an additional $30 million potential from warrant exercises that could extend runway into 2027. Key upcoming catalysts include: OCU410 Phase 2 full data release in Q1 2026, OCU410ST Phase 2/3 interim data (50% of patients at 8 months) mid-year 2026, OCU400 Phase 3 top-line data in Q4 2026, and initiation of BLA rolling submission for OCU400 in H1 2026. The company plans to initiate OCU410 Phase 3 in 2026 and targets a BLA filing for OCU410ST in H1 2027 and for OCU410 in 2028. The company will continue pursuing financing opportunities and strategic business development partnerships to fund operations through commercialization.

OCGN YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$-40,000,000$-20,000,000$0$1.1M$1.8MRevenue$-26,305,970$-17,625,000Operating Income$-44,165,198$-20,051,000Net Income
$-40,000,000$-20,000,000$0RevenueOperating IncomeNet Income

OCGN Revenue by Segment

Collaborative Arrangement Revenue$1.8M

Figures from SEC filings and company reports. Not investment advice.